IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Study for the outcome and safety of individualized busulfan dosing with bortezomib for
patients preparing for a second stem cell transplant to treat multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.